8月13日 - ** 制药公司Omeros（OMER.O）的股价在盘前交易中上涨17%，至16.05美元
** 据伦敦证券交易所集团（LSEG）数据显示，该公司公布第二季度每股盈利15美分，而分析师平均预期为每股亏损27美分
** 得益于其药物Yartemlea的强劲销售，OMER第二季度营收达2850万美元，超出分析师预期的1270万美元
** Yartemlea用于治疗一种罕见但严重的医疗并发症，即小血管内形成血栓，该并发症通常发生在骨髓或干细胞移植之后
** 截至上一交易日收盘，该股年内累计跌幅达20.2%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.